Prefilled Syringe Formulation and Autoinjector Delivery

Prefilled Syringe Formulation Basics: Drug, Container and Device as One System

A prefilled syringe turns the package into part of the dosage form, because the drug sits against glass or polymer, a lubricant and an elastomer throughout shelf life. An autoinjector adds a spring-driven mechanism that the formulation must also work with. Regulators treat the result as a combination product, so formulation scientists need to understand the device and the rules that govern it. The table below maps each part to the question it raises.

Under 21 CFR 3.2(e), a combination product comprises two or more regulated components, such as drug and device, that are combined and produced as a single entity. The EMA's guideline calls the equivalent EU configuration an integral medicinal product. Neither framework treats the syringe as a passive container. Our guides to parenteral formulation development and biologics protein stability cover the formulation side, and the wider category sits under pharmaceuticals and health care.

The first interaction to check is the one the EMA names explicitly: silicone oil.

Syringe Silicone Oil Interaction: Particles, Aggregation and Surfactants

Silicone oil lubricates the plunger in glass syringes, and that same film is a source of droplets that interact with proteins. The EMA guideline states that silicone oils released from the device can nucleate the formation of proteinaceous particles and aggregates with protein products. Peer-reviewed work shows that the size of the effect depends on the barrel, the buffer and the surfactant. Understanding those three levers lets a formulator separate a device effect from a formulation effect.

• Lubricated versus oil-free barrels — a 2015 Journal of Pharmaceutical Sciences study found that oil-free glass and polymer syringes gave similar aggregate and particle levels.
• Lubrication effect — in the same study silicone oil caused insoluble aggregates in most samples, and lubricated glass syringes gave the highest particle counts.
• Buffer — for the same lubricated syringe type, particle counts were higher in acetate buffer than in phosphate-buffered saline.
• Surfactant trade-off — in a 2017 International Journal of Pharmaceutics study, polysorbate 20 limited antibody aggregates during agitation but increased silicone oil droplet numbers.
• Measurement — the 2017 study used three orthogonal techniques because each gave complementary but distinct information on aggregates and droplets between 0.1 and 10 microns.

The immunogenicity question is more nuanced than the particle counts suggest. In a 2015 ovalbumin study in mice, high concentrations of silicone oil microdroplets gave antibody responses equivalent to those from alum, a vaccine adjuvant. Lower levels taken directly from commercial siliconised syringes did not enhance the response significantly. Droplet dose therefore matters, which is why droplet levels are worth controlling and monitoring.

Silicone is only one of the materials the drug contacts, so the barrel and its manufacturing residues come next.

Glass Syringe Protein Stability: Barrel Material, Tungsten and Leachables

Barrel material changes surface chemistry as well as breakage risk. The 2015 study lists the disadvantages of glass as breakage, surface reactivity, the possibility of delaminated glass contamination and the need for silicone lubrication. Cyclic olefin polymer barrels answer some of those problems and bring their own, such as higher susceptibility to scratches and higher gas permeability. Manufacturing residues add a further variable, as the tungsten case below shows.

A 2012 Pharmaceutical Research paper shows how a residue can surprise a development team. Two batches of an epoetin alfa product in syringes showed unusually high aggregation, and soluble tungsten was found in the syringes, most likely from pins used to make them. Spiking the protein with sodium polytungstate, or with an extract of the pins, induced dimers that appeared to be disulphide-linked, and higher-order aggregates. The same paper recalls that replacing albumin with polysorbate 80 and glycine preceded a rise in antibody-mediated pure red cell aplasia. Investigators proposed that polysorbate 80 enhanced leaching from uncoated rubber stoppers.

The barrel advantages and watch-outs above are as reported in the 2015 study, whose polymer syringes were supplied by their manufacturer. The EMA guideline turns the wider lessons into a compatibility checklist for every material that contacts the product:

• Sorption and precipitation — test whether the drug adsorbs to a surface or precipitates in contact with it.
• Extractables and leachables — assess what migrates from device materials and processing aids into the product.
• Worst-case orientation — study compatibility in the orientations and in-use conditions most likely to cause an effect.
• Simulated transport — include vibration and shipping studies where actual transport data are absent.

Compatibility sets what the product can survive, and the device decides what it takes to deliver the dose.

Injection Force, Viscosity and Autoinjector Delivery

A syringe that is stable on the shelf still fails if the patient cannot push the plunger or the autoinjector cannot finish the dose. Viscosity, needle bore and flow rate set the pressure the device must supply. For a Newtonian liquid, the Hagen-Poiseuille equation says the pressure drop rises with viscosity, needle length and flow rate and falls with the fourth power of the needle radius. The equation assumes Newtonian flow, so measured glide force remains the specification test.

• Release tests — the EMA guideline lists delivered dose uniformity, extractable volume, glide force, needle penetration force and delivery time.
• Device tests — it also lists exposed needle length after activation, activation force and lock-out control against over-dosing.
• Primary functions — an open-access 2023 framework paper names holding force, cap removal force, activation force, extended needle length, injection time, dose accuracy and needle guard lockout.
• Fit with the product — the EMA asks applicants to justify the suitability of the device for the drug product, considering its rheological properties.

Patient tolerance is a separate question from device force. A 2015 study in 24 healthy adults injected placebo solutions through 27-gauge, 6 mm needles. It concluded that volumes up to 3 mL and viscosities up to 15 to 20 cP, delivered within 10 seconds, were well tolerated without pain concerns. The paper notes that an autoinjector must stay on the skin, which limits injection time to approximately 10 seconds.

Performance data are only half the file, because regulators also decide how the combination is assessed.

Autoinjector Device Combination Product: US and EU Pathways

A drug in a prefilled syringe or autoinjector is a combination product in the US and an integral medicinal product in the EU. Each system has its own evidence expectations: FDA applies drug and device manufacturing rules to the constituent parts, and the EMA expects device conformity evidence inside the quality dossier. Formulation work feeds both, so the paperwork is worth understanding early.

The EMA guideline, in force from 1 January 2022, adds two points that matter to formulators. The device should be as advanced as possible by the time pivotal trials begin, which reduces the bridging data needed at the marketing authorisation stage. Changes to the product, such as volume or viscosity, can also affect device performance enough to require further verification and validation. Our guide to the pharmaceutical regulatory pathway covers the wider submission framework.

With the technical and regulatory pieces in view, the practical question is how a team assembles the skills to deliver them.

Working With a Pharmaceutical Formulation Consultant and CDMO Support

Prefilled syringe projects cross formulation, packaging, device engineering and regulatory work, and few teams hold all four in-house. A pharmaceutical formulation consultant links the stages so a formulation decision is checked against the container, the device and the dossier before it hardens. Independent pharmaceutical product development services also keep supplier claims separate from measured compatibility data. The sequence matters more than any single study.

• Container screening — comparing glass, polymer, oil-free and lubricated options against the product's buffer and surfactant system.
• Compatibility design — planning sorption, extractables and leachables, agitation and transport studies.
• Injectability — linking viscosity and fill volume to glide force and the autoinjector's capability.
• Technology transfer — preparing the process and specifications for contract formulation CDMO support and scale-up.

Our guide to selecting a CDMO partner covers the transfer stage. Before locking a presentation, run a short decision check. Choose the barrel and lubricant on measured particle data, then confirm the surfactant does not trade aggregates for droplets. Test glide force and delivery time on the final viscosity, and confirm the device and dossier route. A syringe presentation chosen this way rests on evidence, and one chosen by supplier default rests on a catalogue.